**Novartis Pharma AG**
Global Patient Engagement
Development Unit
CH-4002 Basel
Switzerland
https://www.novartis.com

# Community Update

## Update on the Pelacarsen Atherosclerotic Cardiovascular Disease (ASCVD) Clinical Development Program

*This letter has been created by Novartis and is intended for patient organizations, patient advocacy groups, and individual patient advisors.*

October 16, 2026

Dear Patient Organization Partners and Patient Advisors,

Novartis would like to share an update on the pelacarsen ASCVD clinical development program in people with elevated lipoprotein(a) [Lp(a)] and established atherosclerotic cardiovascular disease (CVD).
Following the Lp(a)HORIZON outcome, Novartis has decided to discontinue the pelacarsen ASCVD clinical development program.

We understand that this update is disappointing for the patient community, as well as for the organizations and partners who contributed to this work. These are not the results we hoped for, but they provide important evidence that advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes and may help inform future approaches to cardiovascular risk management.
The Lp(a)HORIZON trial data will be presented at the American Heart Association Conference. Novartis remains committed to driving cardiovascular innovation and to sharing study results in accordance with applicable regulatory and ethical requirements.

Thank you again for your collaboration, time, and thoughtful input throughout this program. We value your continued partnership and your commitment to supporting people affected by cardiovascular disease and elevated Lp(a). We sincerely hope you will continue to support awareness of cardiovascular research and the important contribution of patients who choose to participate.

If you have any questions or would like further information, please do not hesitate to reach out to your Novartis contact.

Warm regards,

**Stuart Byiers**
**Global Program Head**

**Flavia Perna**
**Global Patient Engagement Cardio & Renal**

***This statement is not intended to establish any legally enforceable rights, obligations, or commitments on Novartis***